Triple Combination Immunotherapy for Lung Cancer

Overseen By Daniel Morgensztern

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Washington University School of Medicine

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 0

30 Participants Needed

Trial Summary

What is the purpose of this trial?

This trial is testing a combination of three drugs to help the immune system fight lung cancer. The drugs are zimberelimab, domvanalimab, and etrumadenant. They are being tested on patients who have already tried other immune-based treatments. The goal is to see if this new combination can work better.

Research Team

Daniel Morgensztern

Principal Investigator

Washington University School of Medicine

Eligibility Criteria

This trial is for adults with non-small cell lung cancer who've had previous treatments including immune checkpoint blockers. They must have at least one measurable tumor and cannot have more than two prior therapies in the metastatic setting. Participants need normal organ function, no severe psychiatric issues or substance abuse, not be pregnant/breastfeeding, and can't have certain other cancers or active autoimmune diseases.

Inclusion Criteria

We don't know how the study drugs might affect a developing baby in the womb.

My bone marrow and organs are functioning normally.

My cancer shows PD-L1 expression of 1% or more.

Exclusion Criteria

Pregnant and/or breastfeeding

I have not received any live vaccines in the last 28 days.

You have had allergic reactions to similar drugs as zimberelimab, domvanalimab, etrumadenant, or other drugs used in the study.

Treatment Details

Interventions

• Domvanalimab
• Etrumadenant
• Zimberelimab

Trial Overview The study tests a combination of three drugs: Zimberelimab, Domvanalimab, and Etrumadenant on patients with non-small cell lung cancer who didn't respond well to previous treatments. It explores how these drugs work together since they target different aspects of the immune system's ability to fight cancer.

Participant Groups

Group I: Cohort B: Zimberelimab + Domvanalimab + Etrumadenant Experimental Treatment 3 Interventions

* Patients will be treated on 21-day cycles with 360 mg zimberelimab intravenously on Day 1, 15 mg/kg domvanalimab intravenously on Day 1, and 150 mg etrumadenant orally daily on Days 1 to 21. * Cohort B participants are those that have PD-L1 ≥ 50%.

Group II: Cohort A: Zimberelimab + Domvanalimab + Etrumadenant Experimental Treatment 3 Interventions

* Patients will be treated on 21-day cycles with 360 mg zimberelimab intravenously on Day 1, 15 mg/kg domvanalimab intravenously on Day 1, and 150 mg etrumadenant orally daily on Days 1 to 21. * Cohort A participants are those that have PD-L1 1-49%

Who Is Running the Clinical Trial?

Washington University School of Medicine

Lead Sponsor

Trials

2,027

Recruited

2,353,000+

Arcus Biosciences, Inc.

Industry Sponsor

Trials

44

Recruited

7,500+